• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 441651 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1418918857 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1418918857 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulating Shares of Pharmacyclics on 2.2x Above-Average Volume (PCYC)

Published on Wed, 02/13/2013 - 14:11
By Mallory Stone

Pharmacyclics shares are trading on heavy volume today, having risen 7.5% to $75.66. About 956,000 shares have been traded today, as compared to the 30-day average volume of 434,000 shares. Unusually high volume can signify a potential turning point or validate a breakout.

In the past 52 weeks, Pharmacyclics share prices have been bracketed by a low of $22.70 and a high of $76.00 and are now at $75.66, 233% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 1.2% while the 50-day MA has advanced 1.6%.

Potential upside of 6.7% exists for Pharmacyclics, based on a current level of $75.66 and analysts' average consensus price target of $80.75. The stock should discover initial support at its 50-day moving average (MA) of $64.13 and subsequent support at its 200-day MA of $54.93.

Pharmacyclics, Inc. is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. The Company's products are patented agents derived from its technology platform for designing and synthesizing energy-potentiating drugs.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Expedia (EXPE) Approaches New Upside Tar...

Shares of Expedia (NASDAQ:EXPE) have bullishly opened above the pivot of $86.45 today a ...

Cypress Sharpridge Investments Shares Si...

Cypress Sharpridge Investments (NYSE:CYS), a company whose shares are moving quickly, i ...

Jinpan International Ranks the Lowest in...

Below are the three companies in the Electrical Components & Equipment industry with th ...

EQT (EQT) Breaks Through Resistance at $...

Shares of EQT (NYSE:EQT) opened today above their pivot of $79.56 and have already reac ...

Stock Investors Bid Up Shares of Pegasys...

Pegasystems (NASDAQ:PEGA) is a company whose shares are active, trading 3.5% higher to ...

Top 3 Companies in the Specialized REITs...

Below are the three companies in the Specialized REITs industry with the lowest enterpr ...

Mattel (MAT) Approaches New Upside Targe...

Shares of Mattel (NYSE:MAT) opened today above their pivot of $30.68 and have already r ...

Buyers Accumulate Shares of Harman Inter...

Harman International Industries (NYSE:HAR), a company whose shares are moving quickly, ...